Yes, but management may also consider exclusive licensing deal with performance milestones to somewhat de-risk the binary event.
Maybe ATX are considering a licensing deal with a Major Korean pharma as we speak.
JMHO, DYOR.
News: ATX Amplia Therapeutics Says Approval From Korean Regulator, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.010(5.71%) |
Mkt cap ! $89.99M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 17.0¢ | $1.746M | 9.554M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 196996 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 287768 | 7 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| ATX (ASX) Chart |